Oxator 100 Mg (Oxaliplatin) Injection

Introduction

Oxator 100 mg (Oxaliplatin) Injection represents an advanced formulation in the treatment of colorectal cancer, offering a higher concentration option for optimal dosing flexibility. This platinum-based antineoplastic agent, manufactured by Eskayef Pharmaceuticals Ltd. and distributed by Orio Pharma, delivers precise and potent therapy for both adjuvant treatment of stage III colon cancer and management of advanced colorectal cancer. The 100 mg strength provides efficiency in preparation and administration, particularly for patients requiring higher doses based on body surface area calculations. With Orio Pharma’s commitment to worldwide delivery within 3-7 working days, healthcare providers gain timely access to this essential oncology medication, enhancing treatment outcomes for colorectal cancer patients globally.

Clinical Applications

Oxator is specifically indicated for use in combination with infusional 5-fluorouracil/leucovorin in two primary clinical scenarios:

Adjuvant Treatment of Stage III Colon Cancer

For patients who have undergone complete resection of the primary tumor
Provides critical post-surgical therapy to eliminate microscopic disease
Significantly reduces the risk of disease recurrence
Improves disease-free survival and overall survival metrics
Standard component of post-surgical care for eligible patients

Advanced Colorectal Cancer Management

Effective treatment for metastatic or locally advanced disease
Delivers meaningful improvement in progression-free survival
Essential component of first-line and subsequent treatment regimens
Maintains quality of life while addressing disease progression
Demonstrates effective tumor response rates in combination therapy

Mechanism of Action

Oxator’s therapeutic efficacy stems from its sophisticated platinum-based mechanism:

Platinum Complex Design: Structurally similar to cisplatin but with improved toxicity profile
Alkylating Properties: Creates cross-links within and between DNA strands
Cellular Activation: Undergoes intracellular hydrolysis to become biologically active
DNA Binding: Forms both inter- and intra-strand DNA cross-links
Replication Inhibition: Prevents DNA replication and transcription processes
Apoptosis Induction: Triggers programmed cell death in affected cancer cells

This multi-step mechanism makes Oxator particularly effective against rapidly dividing colorectal cancer cells while working synergistically with fluoropyrimidines like 5-fluorouracil in combination regimens.

Dosage and Administration Guidelines

Precise administration of Oxator 100 mg is essential for optimal therapeutic outcomes:

Adjuvant Therapy for Stage III Colon Cancer

Standard Dose: 85 mg/m² administered intravenously every 2 weeks for 12 cycles
Administration Method: IV infusion over 2-6 hours, dissolved in 250-500 ml of 5% glucose solution
Toxicity Management: Reduce to 75 mg/m² after recovery from significant toxicity
Treatment Sequence: Administer before fluoropyrimidines in combination protocols

Advanced Colorectal Cancer Treatment

Standard Dose: 85 mg/m² administered intravenously every 2 weeks
Duration: Continue until disease progression or unacceptable toxicity
Administration Method: IV infusion over 2-6 hours, dissolved in 250-500 ml of 5% glucose solution
Toxicity Management: Reduce to 65 mg/m² after recovery from significant toxicity
Treatment Sequence: Administer before fluoropyrimidines in combination protocols

The higher concentration 100 mg vial provides efficiency in preparation, particularly for patients with larger body surface areas, reducing the number of vials needed per dose.

Important Clinical Considerations

Contraindications

Oxator is contraindicated in the following situations:

Pregnancy (Category D)
Peripheral neuropathy with functional impairment
Severe renal impairment

Drug Interactions

Healthcare providers should be mindful of these potential interactions:

May decrease plasma levels of digoxin
Increased risk of toxicity when combined with nephrotoxic medications
When used with taxane derivatives (docetaxel, paclitaxel), sequential administration is recommended with taxanes given before Oxator

Adverse Effects Profile

Common adverse reactions include:

Neurological: Peripheral neuropathy, dizziness, headache, pharyngolaryngeal dysesthesia
Gastrointestinal: Nausea, diarrhea, vomiting, abdominal pain, constipation, anorexia, stomatitis
Hematological: Anemia, thrombocytopenia, leukopenia, neutropenia
Hepatic: Elevated liver enzymes (AST, ALT), increased bilirubin
Constitutional: Fatigue, fever, pain, insomnia
Dermatological: Rash, alopecia, hand-foot syndrome
Respiratory: Dyspnea, cough, rhinitis, epistaxis
Other: Electrolyte disturbances, injection site reactions, arthralgia

Clinical Precautions

Oxator administration requires significant clinical vigilance:

Specialized Oversight: Should be administered under the supervision of physicians experienced in cancer chemotherapy
Safe Handling: Follow appropriate precautions for handling and disposal of cytotoxic agents
Neurological Monitoring: Regular assessment of neurological status with dose adjustments for prolonged or severe symptoms
Hematological Management: Monitor blood counts during treatment with appropriate delays until recovery
Equipment Selection: Avoid aluminum-containing needles or IV administration sets as aluminum may degrade platinum compounds
Special Populations: Use with caution in elderly patients and those with moderate renal impairment
Lactation: Not recommended during breastfeeding due to potential risks

Preparation and Storage

Proper preparation and storage are critical for maintaining Oxator’s efficacy:

Reconstitution Protocol

For 100 mg vial: Reconstitute with 20 ml of water for injection or 5% dextrose
Further Dilution: Reconstituted solution must be further diluted with 250-500 ml of 5% dextrose injection before administration

Storage Requirements

Intact Vials: Store at 15-30°C; do not freeze
Reconstituted Solution: May be stored at 2-8°C for up to 24 hours
Diluted Solutions: Stable for up to 6 hours at 20-25°C or up to 24 hours under refrigeration (2-8°C)

Manufacturing Excellence

Oxator 100 mg is manufactured by Eskayef Pharmaceuticals Ltd., a premier pharmaceutical company with over three decades of excellence in medication production. Since its inception in 1990, when Eskayef acquired the Bangladesh operation of SK&F, USA, the company has established itself as a leader in pharmaceutical manufacturing. Their commitment to stringent quality control and adherence to international standards ensures that each vial of Oxator 100 mg meets the highest benchmarks for efficacy, safety, and reliability.

Supplier

Orio Pharma serves as the dedicated supplier for Oxator 100 mg, specializing exclusively in high-quality oncology medications. Founded in 2019, Orio Pharma is driven by core values of compassion, integrity, innovation, and collaboration. Their commitment to worldwide delivery within 3-7 working days addresses the critical time-sensitive nature of cancer treatment, ensuring that healthcare providers can initiate and maintain treatment protocols without delays. Orio Pharma’s specialized focus on oncology products ensures expert handling and support throughout the supply chain.

Conclusion

Oxator 100 mg (Oxaliplatin) Injection represents a significant advancement in colorectal cancer treatment. Its higher concentration formulation provides efficiency in dose preparation while delivering the proven efficacy of oxaliplatin in both adjuvant therapy for stage III colon cancer and treatment of advanced colorectal cancer. Manufactured to exacting standards by Eskayef Pharmaceuticals and supplied with dedication by Orio Pharma, Oxator 100 mg delivers the quality, reliability, and therapeutic efficacy that healthcare professionals and patients depend on. With comprehensive dosing guidelines, detailed safety information, and global availability through rapid delivery services, Oxator 100 mg stands as an essential component in modern colorectal cancer treatment protocols, offering hope and improved outcomes for patients battling this challenging disease.

For complete prescribing information, clinical support, or to place an order, healthcare professionals are encouraged to contact Orio Pharma’s specialized oncology team today.